The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.
about
Importance of immune response genes in hemophilia AStructural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junctionA3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IXDimeric Organization of Blood Coagulation Factor VIII bound to Lipid Nanotubes.Molecular defects in coagulation Factor VIII and their impact on Factor VIII function.Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain.Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action.Mild hemophilia A.Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors?Factor VIII - novel insights into form and function.Molecular mechanisms of mild and moderate hemophilia A.Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase.Molecular basis of haemophilia A.Strategies towards a longer acting factor VIII.Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIaMembrane-binding properties of the Factor VIII C2 domain.Identification of residues in the 558-loop of factor VIIIa A2 subunit that interact with factor IXaThe N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody.Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition.Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction.Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.The Factor VIII Mutation Database on the World Wide Web: the haemophilia A mutation, search, test and resource site. HAMSTeRS update (version 3.0).The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism.Mapping of the factor Xa binding site on factor Va by site-directed mutagenesisCa2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding.Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity.Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.Identification of plasmin-interactive sites in the light chain of factor VIII responsible for proteolytic cleavage at Lys36.Detection of new mutations and molecular pathology of mild and moderate haemophilia A patients from southern Brazil.Factor IXa:factor VIIIa interaction. helix 330-338 of factor ixa interacts with residues 558-565 and spatially adjacent regions of the a2 subunit of factor VIIIa.Defining the factor Xa-binding site on factor Va by site-directed glycosylation.Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII.Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein.The Gla domain of factor IXa binds to factor VIIIa in the tenase complex.A domain mutations in 65 haemophilia A families and molecular modelling of dysfunctional factor VIII proteins.Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function.Genetic diagnosis in Hemophilia A from southern China: five novel mutations and one preimplantation genetic analysis.Expression studies of mutant factor VIII alleles with premature termination codons with regard to inhibitor formation.
P2860
Q27025467-3AFE35B6-2F2E-4842-A443-A1CEB981280EQ27667771-2269D8F3-6207-4AA8-A1A4-B1075917CF7DQ30352313-06AFC5B4-A17B-4DA4-8445-A5B9C7FE3D17Q30384710-463D62D0-2FAE-474B-9355-6C4B7A6279E1Q34146618-095194F6-0396-480A-804D-C59F0D834C47Q34451013-3038B237-ED78-4FDF-A768-4B52BA136CADQ34557048-16EB54AC-8290-4CE6-9521-7AF9B1950AE8Q34614695-A95CBAA6-AAF1-409C-A3B8-91DD6079303EQ34983308-6C6F1191-9620-4BF1-8434-F1167EFFAB34Q34983313-7D97EAC8-207B-4157-8EAE-131B0D188DE2Q35181733-56FB97B5-CD61-4D55-B596-6D495352F248Q35819426-7E94FEEB-3EF5-414C-A56B-48061128F035Q35915713-3E16C0D5-5F70-465A-883D-EAFB2F7DBAD3Q36473043-CD8D4253-048A-442C-AAD8-A08446FA9E08Q36621449-47AF27D6-F69C-4D30-B503-B4648E3DB0EDQ36896861-1A9A99DD-D37D-4C2F-A822-E30729DCA7E8Q37431901-1533299D-7749-45F0-A2D0-91E407EB53CAQ38287370-BC14DAD3-BF94-4C46-9A41-1CCD99E1E095Q38308725-AF93A986-2D4F-4F48-84CD-58957DAA8D7FQ38319976-68025604-FF7A-4047-8AC8-FCC76004934BQ38792889-9B75F01F-DF3B-43BC-AAE4-53FD030770ADQ39718715-0AC799D8-C8C7-452F-828F-9BC474D317EEQ39722507-E91CFD89-AB8E-4151-B978-86A5000E15CEQ40284089-C421401B-81A4-470E-89EE-8147F62B964CQ40422254-B162BA38-ADB1-464E-8BA7-B4EC824334EDQ41159184-08891A6C-8862-47DC-B19A-5B931CAADD35Q41788714-9B327767-0AB7-4427-8BD4-FB9A405DD98DQ42026523-618FA9DE-222F-4DCC-A798-BE5B0A0C8C2BQ43167061-04D050D5-E0CF-4C28-99D8-6910518D1514Q43493283-78D9BDCF-6B99-40F0-8E68-5C89F361AC50Q43560122-B6961E0B-CD0C-4CA8-A7D8-8EFF67615777Q44183079-74C0BD0A-41C3-4FF1-A567-43AD413BACB2Q44274593-6FEFCB78-39D3-45C1-9859-A4FFEB133728Q44274672-3826D3B8-C3D7-41E2-8E87-02EB1149612BQ44463045-99C71487-5F12-4F1E-BC9B-86F76781798AQ45855580-207DE1BC-4AE9-4A1E-B6B2-7D5767850FDDQ45858392-CA581F26-D348-4F08-AB44-96509E3ABA8DQ45861953-0A715B9F-006D-4D14-A4C8-2AF66E53733EQ45862031-B9419864-3C4B-4393-9ADB-CD346C157F62Q45863066-1111A232-8519-43B2-B595-68D122AD1E88
P2860
The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
The sequence Glu1811-Lys1818 o ...... site for activated factor IX.
@en
type
label
The sequence Glu1811-Lys1818 o ...... site for activated factor IX.
@en
prefLabel
The sequence Glu1811-Lys1818 o ...... site for activated factor IX.
@en
P2093
P2860
P356
P1476
The sequence Glu1811-Lys1818 o ...... site for activated factor IX.
@en
P2093
Lenting PJ
van Mourik JA
van de Loo JW
P2860
P304
P356
10.1074/JBC.271.4.1935
P407
P577
1996-01-01T00:00:00Z